

# 参考文献 (続き)

- Visseaux B, Assoumou L, Mahjoub N, et al. Surveillance of HIV-1 primary infections in France from 2014 to 2016: Toward stable resistance, but higher diversity, clustering and virulence? *J Antimicrob Chemother.* 2020;75(1):183-193.
- Wang R, Wright J, Khaled, et al. Assessing the virologic impact of archived resistance in an HIV-1 Switch Study TANGO Through Week 48. Program and abstracts of the 2020 Conference on Retroviruses and Opportunistic Infections. March 8-11, 2020. Boston, Massachusetts (Virtual). Abstract 59.
- Weinheimer S, Marsolais C, Cohen Z, et al. Ibalizumab susceptibility in patient HIV isolates resistant to Antiretrovirals. Program and abstracts of the 2018 Conference on Retroviruses and Opportunistic Infections. March 4-7, 2018. Boston, MA. Abstract 561.
- Wensing AM, Calvez V, Ceccherini-Silberstein F, et al. 2019 update of the drug resistance mutations in HIV-1. *Top Antivir Med.* 2019;27(3):111-121.
- Wijting I, Rokx C, Boucher C, et al. Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. *Lancet HIV.* 2017;4(12):e547-e554.
- World Health Organization. Guidelines on the public health response to pretreatment HIV drug resistance, July 2017. Geneva: World Health Organization; 2017. License: CC BY-NC-SA 3.0 IGO. Available at: <https://www.who.int/hiv/pub/guidelines/hivdr-guidelines-2017>. Accessed May 12, 2020.
- Yang W, Kouyos R, Scherrer A, et al. Assessing the paradox between transmitted and acquired HIV type 1 drug resistance mutations in the Swiss HIV cohort study from 1998 to 2012. *J Infect Dis.* 2015;212:28-38.
- Yang D, Lai J, Cal S, et al. HIV resistance-associated mutations observed in cell-associated DNA sequencing assay. Program and abstracts of the 2019 Conference on Retroviruses and Opportunistic Infections. May 4-7, 2019. Seattle, WA. Abstract 543.
- Young, Fransen S, Greenberg KS, et al. Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy. *Antivir Ther.* 2011;16:253-256.
- Zhou N, Nowicka-Sans B, McAuliffe B, et al. Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068. *J Antimicrob Chemother.* 2014;69:573-581.